The study involved the examination of 20 MDS patients, with aberrant CLL-1 expression mainly observed in 8 patients with MDS with excess blasts and, to a lesser extent, in 12 patients with low-risk MDS [37]. The gene discussed is CLEC12A; the disease is myelodysplastic syndrome.